Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide analysis of HL60 cells after 24h pulse of 10nM vincristine

ABSTRACT: Analysis of HL60 response to low-dose vincristine at gene expression level. The hypothesis tested in the present study was that population heterogeneity has functional consequences in drug response. Since the presence of discrete efflux^High and efflux^Low subpopulations may reflect transitions between distinct stable cellular states (attractor states), we measured the transcriptomes when the cell population exhibited a stable bimodal distribution. We also measured the transcriptomes for 17 days after washing the drug (samples 5 - 9). Total RNA obtained from HL60 cells untreated (sample 3), treated for 24h (sample 4) and sorted after 24h treatment for Calcein AM efflux low (sample 1) and high (sample 2). Sample 5 corresponds to total RNA of untreated cells, sample 6 to total RNA after 24h treatment with 10nM vincristine and samples 7 to 9 to total RNA after washing the drug.

ORGANISM(S): Homo sapiens

SUBMITTER: Sui Huang

PROVIDER: E-GEOD-49869 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Genome-wide analysis of HL60 cells after 24h pulse of 10nM vincristine

Project description:Analysis of HL60 response to low-dose vincristine at gene expression level. The hypothesis tested in the present study was that population heterogeneity has functional consequences in drug response. Since the presence of discrete efflux^High and efflux^Low subpopulations may reflect transitions between distinct stable cellular states (attractor states), we measured the transcriptomes when the cell population exhibited a stable bimodal distribution. We also measured the transcriptomes for 17 days after washing the drug (samples 5 - 9).

2013-08-15 | GSE49869 | GEO

Transcriptional Regulation of HL60 Neutrophil Differentiation: Promyelocyte trajectory vs. Neutrophil trajectory

Project description:Using the HL60 multipotent promyelocytic leukemia cell line, we performed experiments that lead to two different cell fate attractors by treatments of varying dosage and duration of the differentiation agent all-trans-retinoic acid (ATRA). The dosage and duration combinations corresponding to the two treatments were chosen by means of of cytometric measurements of CD11b, a well-known early differentiation marker, such that the two populations are poised at the same stage of differentiation. Using the selected treatment combinations, one population proceeds toward the terminally differentiated neutrophil attractor while the other population reverts back toward the undifferentiated promyelocytic attractor. We monitored the gene expression changes in the two populations after their respective treatments over a period of five days and identified a set of genes that diverged in their expression; a subset of which promotes neutrophil differentiation while the other represses cell cycle progression. By employing promoter based transcription factor binding site analysis, we found enrichment of transcription factors functionally linked to tumor progression, cell cycle, and development. Keywords: Time course, dose response Untreated HL60 cells are hybrized on the channel 1 with Cy3, ATRA-Treated HL60 cells are hybridized on channel 2 with Cy5. HK60 cells were treated with high dosage/short duration and low dosage/long duration to achieve 55% of CD11b+ cells. These positive cells were then isolated and culture in fresh media and total RNA were isolated for comparison. Cells treated with high dosage/short duration treatment proceed toward the neutrophil attractor while cells treated with the low dosage/long duration treatment revert back toward the promyelocyte attractor.

2008-11-19 | E-GEOD-13673 | biostudies-arrayexpress

Homo sapiens

Project description:Genome-wide analysis of HL60 cells after 24h pulse of 10nM vincristine

| PRJNA215198 | ENA

Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells

Project description:Gene expression profiles were assessed for vincristine-sensitive parental ovarian tumor cell line (SKOV3) and its highly vincristine-resistant derivative (SKVCR 2.0) Keywords: vincristine, drug resistance, ovarian, SKOV3, MDR

2007-08-24 | GSE7556 | GEO

Transcriptome-wide analysis of RNA N6-methyladenosine in Adriamycin-resistant acute myeloid leukemia cells

Project description:N6-Methyladenosine (m6A) is the most abundant post-transcriptional modification in eukaryotes, the imbalance of which is reported to be associated with various pathological processes, including drug resistance. In this study, we analyzed the methylated RNA immunoprecipitation combined with next-generation sequencing (MeRIP-seq) data of AML cell line HL60 and its adriamycin-resistant cell line HL60/ADR. We found a total of 40550 peaks, representing 15640 genes in HL60, and a total of 38834 peaks, representing 15285 genes in HL60/ADR. A total of 4437 differentially methylated m6A peaks within 3461 genes have been found between HL60 and HL60/ADR. Among them, 3587 differentially m6A peaks within 2790 genes were hyper-methylated, and 850 m6A peaks within 671 genes were hypo-methylated. KEGG pathway analysis showed that pathways were enriched in tumor and drug-resistant related signaling pathway. Results of MeRIP-seq showed that fold enrichment of global m6A peaks was higher in HL60/ADR compared to HL60. This study provides a framework for the application of comprehensive mRNA m6A profiling towards acute myeloid leukemia cell line (HL60) and its adriamycin-resistant acute myeloid leukemia cell line (HL60/ADR).

2021-12-29 | GSE192618 | GEO

Transcriptional Regulation of HL60 Neutrophil Differentiation: Promyelocyte trajectory vs. Neutrophil trajectory

2008-11-20 | GSE13673 | GEO

Deep mutational scan of a drug efflux pump reveals its structure-function landscape

Project description:Drug efflux is a common resistance mechanism found in bacteria and cancer cells. Although several structures of drug efflux pumps are available, they provide only limited functional information on the phenomenon of drug efflux. Here, we performed deep mutational scanning (DMS) on the bacterial ATP binding cassette (ABC) transporter EfrCD from Enterococcus faecalis to determine the drug efflux activity profile of more than 1400 single variants

2021-11-25 | GSE189399 | GEO

mRNA-sequencing in drug-resistant acute myeloid leukemia

Project description:mRNA sequencing for AML cells(HL-60) and drug-resistant AML Cells(HL60/MX2).

2022-04-23 | GSE201095 | GEO

m7G-MeRIP-sequencing of mRNA in drug-resistant acute myeloid leukemia

Project description:m7G-MeRIP-sequencing for AML cells(HL-60) and drug-resistant AML Cells(HL60/MX2).

2022-04-23 | GSE201096 | GEO

Sequencing of matched pair samples (diagnosis and relapse) in human B-cell acute lymphoblastic leukemia cells (ALL)

Project description:The experiment focused on how B-cells respond transcriptionally to drug treatment in acute lymphocytic leukemia (ALL). We obtained B-cell samples from a patient at diagnosis (LAX7) and after the development of resistance (LAX7R) following a standard 3-week chemotherapy regimen (vincristine, dexamethasone, L-asparaginase and doxorubicin). The resistance sample possessed a KRASG12V mutation not present at diagnosis. Cells obtained from the patient were directly engrafted into NOD/SCIDγc-/- mice, and later frozen as stocks.

2018-02-12 | GSE102301 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data